41results about How to "Solve the problem of low dissolution rate" patented technology

The invention relates to a cefprozil submicron emulsion solid preparation and new application thereof in the preparation of medicine for treating acute plasma cell mastitis. The cefprozil submicron emulsion granule comprises cefprozil, yolk lecithin, poloxamer 188 and deoxysodium cholate with the weight ratio of 1:2.3-14:1.2-8:0.8-10.

The invention relates to a cefixime submicro-emulsion solid preparation and a novel application thereof, in particular to a solid preparation of cefixime processed by micro-emulsification and a novel application thereof. The cefixime submicro-emulsion solid preparation comprises cefixime, an emulsifying agent and an emulsifying aid agent, wherein the active component of the cefixime is processed by applying a micro-emulsification technology. The stability is enhanced, the solubility is increased, and the problem of low leaching degree is solved.

The invention discloses an orlistat oral preparation and a preparation method thereof. The orlistat oral preparation is an orlistat tablet. The orlistat tablet comprises an orlistat acrylic resin solid dispersion, a disintegrating agent and pharmaceutically acceptable auxiliary materials. The orlistat acrylic resin solid dispersion is prepared by rapid expansion of supercritical solution and has D90 less than 10 microns. The raw materials of the orlistat oral preparation are micronized by a supercritical technology and an inert material layer is coated on the orlistat surface so that the problems of a low dissolution rate of the preparation obtained by the prior art, and sticking in tabletting are solved.

The invention discloses a method for preparing telmisartan and amlodipine double-layer tablets. The double-layer tablets comprise a telmisartan layer and an amlodipine besylate layer, wherein the telmisartan exists in a solid dispersion form. According to the method for preparing telmisartan and amlodipine double-layer tablets provided by the invention, good dissolution behaviors of the telmisartan and amlodipine besylate are guaranteed, and high stability of the amlodipine besylate is also guaranteed, so that the quality and curative effects of the telmisartan and amlodipine double-layer tablets are ensured. The preparation method is simple and feasible and is suitable for industrial production.

The invention discloses an infantile domperidone orally disintegrating tablet and a preparation method thereof. The orally disintegrating tablet is prepared from the following raw materials in parts by mass: 10 to 30 parts of domperidone, 10 to 30 parts of fatty glyceride, 5 to 10 parts of tween 80, 900 to 2700 parts of white sugar, 2 to 5 parts of crospovidone, 10 to 30 parts of mannitol, 0.01 to 0.05 part of essence, 0.2 to 0.5 part of magnesium stearate and 0.2 to 0.5 part of aerosil. According to the infantile domperidone orally disintegrating tablet and the preparation method thereof, an orally disintegrating tablet medicament is prepared by using the domperidone as an effective component of the medicament and through an innovative process. By using the domperidone orally disintegrating tablet prepared by the invention, the problems that the dissolution rate of the medicament is low, the medicament has a bitter taste, and the like, are solved successfully; the infantile domperidone orally disintegrating tablet has a favorable effect on infantile functional dyspepsia.

The present invention provides one kind of medicine composition of benazepril and its preparation process. The present invention solves the problem of benazepril with low dissolution and the problems of the preparation process in medicine sticking and medicine degradation. The preparation process combines solid dispersing technology and traditional tablet preparation, and is simple, accurate in dosage control and high in production efficiency.

The invention relates to a Canagliflozin tablet composition, and belongs to the technical field of medicine preparations. The technical scheme is that the unit dose of Canagliflozin composition is prepared from 100 to 300 mg of canagliflozin with D90 being 36 to 60 micrometers, 40 to 70 mg of lactose, 0.8 to 1.5 mg of lauryl sodium sulfate, 7 to 15 mg of sodium citrate, 3 to 6 mg of sodium carbonate, 10 to 18 mg of beta-cyclodextrin, 3 to 8 mg of povidone K30, 3 to 8 mg of polyvinylpolypyrrolidone and 1 to 1.5mg of magnesium stearate. The technical scheme provides the Canagliflozin tablet composition with the advantages of high dissolution rate and stability.

The invention discloses a preparation method for microcrystalline cellulose capable of increasing the drug dissolution rate and belongs to the technical field of pharmacy. The preparation method for the microcrystalline cellulose capable of increasing the drug dissolution rate comprises the following steps that raw materials are put into a reaction still containing acid liquor, a steam valve is opened to heat up, and a temperature reaction is maintained; water is added into a storage tank, materials after the reaction in step (1) are added into the storage tank, and still standing is conducted after even stirring to enable the materials to be layered; the upper layer thick liquid of the material part after still standing is extracted for 1/4-3/4 and then subjected to centrifugal washing, after the thick liquid is spin-dried and washed till the pH value of water outflowing from an water outlet of a centrifugal machine is 6-7, washing is stopped, centrifuge dripping is continuous, and a material A is obtained; the material A after centrifuge dripping is dried, the dried material A is obtained; and pulverizing and sieving are conducted, specifically, the dried material A obtained from the last step is evenly added into a pulverizer to be pulverized, and microcrystalline cellulose A, namely microcrystalline cellulose capable of improving the drug dissolution rate, is prepared after pulverizing and sieving. According to the preparation method for the microcrystalline cellulose capable of increasing the drug dissolution rate, the defect that the dissolution rate of traditional microcrystalline cellulose for an indissolvable drug is low and unstable is overcome.

The invention discloses a valsartan and hydrochlorothiazide compound preparation and a preparation process thereof. The preparation process comprises the following steps: pretreating raw materials; pretreating auxiliary materials; preparing dispersion: dispersing valsartan on the surface of the carrier by adopting a supercritical fluid impregnation technology; preparing inclusion compound: carrying out inclusion on hydrochlorothiazide by adopting sulfobutyl ether-beta-cyclodextrin; preparing pre-coated particles: conducting top spraying granulation on the hydrochlorothiazide inclusion compound through a composite adhesive; premixing: mixing the valsartan solid dispersion, the auxiliary materials and the hydrochlorothiazide pre-coated particles; distributing materials: dividing the premixed powder into two parts; respectively carrying out dry granulation on the two parts of premixed powder; mixing totally; tabletting; and coating to obtain the product. The compound preparation with good bioavailability and drug stability is prepared by combining a supercritical impregnation technology, a secondary inclusion technology and a different oil pressure powder granulation technology, the production cost is low, and the process is simple and easy to implement.

The invention discloses a high-dissolubility fenofibrate tablet and a preparation method thereof. The high-dissolubility fenofibrate tablet is prepared by coating a fenofibrate raw material with docosahexaenoic acid-beta-cyclodextrin, performing spray-drying and mixing and directly tabletting with auxiliary materials. By adopting the preparation method disclosed by the invention, the problems that by using a conventional method, the dissolubility is low and the bioavailability is poor as the mass of medicines is hard to control are solved; and compared with a conventional direct tabletting and wet-method pelleting process, the preparation method has the advantages that the dissolubility of medicines is effectively improved, the medicines are relatively good in dissolubility effect and the bioavailability is improved.

The invention belongs to the technical field of surface treatment of medical equipment and relates to a stainless steel matte finishing process. The primary technical scheme is as follows: the stainless steel matte finishing process comprises the following steps: placing a deoiled stainless steel workpiece and the anode of a power supply connected in an anodizing matte finishing solution of a mixture containing 10-50 g/L H3PO4, 10-30 g/L C6H8O7, 100-300 g/L H2O2 and 0.4-1 g/L K2SO4; heating the solution to 60-80 DEG C and connecting a platinum and titanium net to the cathode of a direct current power supply, wherein the area ratio of the platinum and titanium net and the cathode of the direct current power supply is 1: 1; and keeping the distance between the cathode and the anode at 6.0 cm, carrying out anodizing for 30-60 min under the condition that the current density is 3.4-6.8 A/dm<2> and the working voltage is 9.4-10.5 V, wherein the surface of stainless steel workpiece is matteand has silver metal gloss, the hardness of the stainless steel is improved, and the pitting corrosion resistance is improved. The stainless steel matte finishing process provided by the invention notonly can solve the environmental problem that an existing stainless steel matte finishing solution contains harmful substances and strong acids, but also can solve the problem that the dissolving speed of the environment-friendly solution is low, thereby providing a new path for development of stainless steel matte technical treatment.

The invention discloses a method for improving the dissolution rate of cefquinome sulfate and a method for detecting the dissolution rate of the cefquinome sulfate. The method comprises the followingsteps of 1) mixing soybean oil for injection and ethyl oleate according to a ratio of 5: 5, heating mixed liquid to 120 DEG C under the protection of N2, keeping the temperature for 2 hours, and cooling the liquid to the room temperature; 2) heating the mixed liquid to 60 DEG C, adding BHT, performing stirring and melting, adding hydrogenated castor oil and span 60 when the liquid is cooled to 40DEG C, performing stirring for 30 minutes, and performing cooling to the room temperature; and 3) adding a prescription amount of the cefquinome sulfate after all medicinal auxiliary materials are added, pouring the cefquinome sulfate into a colloid mill, and performing grinding for 5-20 minutes in a manner of alternating circulating grinding and non-circulating grinding. The particle size of thecefquinome sulfate is changed through the colloid mill, so that the drug dissolution rate of the cefquinome sulfate is increased; and through particle size detection and dissolution rate analysis, after grinding is conducted for 15-20 min, the cefquinome sulfate with the particle size of 10 microns or below accounts for 80%, and the dissolution rate is the best.

The invention relates to a preparation composition containing pitavastatin calcium tablets, and belongs to the technical field of medicines. The technical scheme is that 1000 tablets of the preparation composition comprise 1-2 g of pitavastatin calcium of which the D90 is 25 [mu]m, 30-70 g of lactose, 10-60 g of microcrystalline cellulose, 8-15 g of mannitol, 3.0-16 g of low substituted hydroxypropyl cellulose, 0.15-0.5 g of sodium carboxymethyl cellulose and 0.5-1.0 g of magnesium stearate. According to the technical scheme, through the addition of mannitol and reasonable control of the granularity, the problems of relatively low dissolvability and nonuniform content of the tablets are solved.

The invention discloses a proglumide pharmaceutical composition. The pharmaceutical composition is characterized in that each 1000 tablets contain the following components in percentage by weight: 190-210 parts of proglumide, 40-210 parts of calcium hydrogen phosphate, 1-5 parts of magnesium stearate and 0-5 parts of a binding agent. A preparation method of the composition comprises the following steps. The pharmaceutical composition disclosed by the invention has advantages that the calcium hydrogen phosphate, which is alkaline, serves as an accessory material, and the proglumide is slightly soluble in water but is solution in an alkaline solution. By virtue of the alkaline accessory material, various quality indexes of a finished product are kept basically stable within a valid period, and moreover the dissolution rate of the product is improved. The calcium hydrogen phosphate, which serves an accessory material, can accelerate disintegration of the finished product while addition of a disintegrating agent, so that cost of the finished product can be reduced.

The invention relates to a nilotinib composition, belonging to the technical field of pharmacy. The nilotinib composition is characterized in that a unit dose of the composition is prepared from 200mgof nilotinib, 36-60mg of chitosan, 36-52mg of lactose, 7-10mg of crospovidone, 4-8mg of alginic acid, 1-3mg of fumed silica, 0.8-1.6mg of sodium dodecyl sulfate and 1.3-2.6mg of magnesium stearate. The stable nilotinib tablet composition with a high dissolution rate can be obtained.

The invention relates to an Ambrisentan tablet composition, and belongs to the technical field of pharmacy. Per thousand tablets of Ambrisentan tablet composition comprise 5 to 10g of Ambrisentan, 32to 50g of lactose, 6 to 12g of calcium hydrophosphate, 16 to 28g of superfine silica gel powder, 28 to 50g of microcrystalline cellulose, 1.5 to 4g of croscarmellose sodium and 0.8 to 1.6g of magnesium stearate. The invention provides the qualified Ambrisentan tablet composition; and the problems of low dissolution rate and low content uniformity of the tablet in the preparation process are solved.

The invention discloses a water treatment aeration tank. The water treatment aeration tank comprises a tank body, gas storage tanks are fixedly mounted in the tank body, air inlet units are fixedly mounted in the tank body, each gas storage tank comprises a tank body, a groove and support columns, the tank body is fixedly mounted in the tank body through the support columns, the groove is disposedat the middle of a space below the tank body, each air inlet unit comprises a draught fan and a pipeline, one end of the pipeline is fixedly connected to an air outlet end of the draught fan, the other end of the pipeline is connected to the upper part inside the groove, three or more gas storage tanks and air inlet units are disposed in the tank body, the top view of the groove body is rectangular or circular, and a water inlet is arranged on one side of the tank body. The water treatment aeration tank is designed through the structures of the gas storage tanks and the air inlet units, the contact area and contact time of air and sewage in the aeration tank is increased, also the sewage boosts the air, and the dissolution rate of oxygen in the air in the sewage is greatly increased.